Diagnostic efficacy of 99mTc-FAPI SPECT/CT
Phase 1
- Conditions
- Malignant neoplasm.Malignant neoplasmC00-C96
- Registration Number
- IRCT20210612051548N5
- Lead Sponsor
- Boushehr University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Volunteering to participate in clinical trials and signing an informed consent form (signed by participant, parent, or legal representative)
Patients with suspected or new diagnosed or previously treated malignant tumors
Inconclusive findings on imaging modalities.
Exclusion Criteria
Pregnant and lactating women
The inability or unwillingness of the research participant, parent, or legal representative to provide written informed consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Target/Background ratio of 99mTc-FAPI SPECT/CT in Diagnosis of malignancies. Timepoint: 99mTc-FAPI Imaging at 1and 4 hours after the administration of the Radiotracer. Method of measurement: SPECT/CT scanner.
- Secondary Outcome Measures
Name Time Method